Real-world analysis of subsequent-line strategies for EGFR C797S mutant non-small cell lung cancer patients acquired resistance to third-generation EGFR tyrosine kinase inhibitors
Jianlin Xu, Anshun Zhu, Yingqi Xu, Yidan Zhang, Yinchen Shen, Yongliang Niu, Hua Zhong, Runbo Zhong · 2025
Read Real-world analysis of subsequent-line strategies for EGFR C797S mutant non-small cell lung cancer patients acquired resistance to third-generation EGFR tyrosine kinase inhibitors by Jianlin Xu, Anshun Zhu, Yingqi Xu, Yidan Zhang, Yinchen Shen, Yongliang Niu, Hua Zhong, Runbo Zhong (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12723867.txt.
Description
Jianlin Xu and seven colleagues published a real-world analysis in two thousand twenty-five on lung cancer after targeted drugs fail. A mutation called C797S commonly defeats third-generation EGFR inhibitors. What to give next was guided by little evidence.
Forty-four patients with the mutation and full records were compared across follow-up regimens. Chemotherapy-based care beat non-chemotherapy care on time without progression, five point five versus three point four months. Adding a blood-vessel blocker to chemotherapy did best. Subgroup patterns differed by whether a second mutation coexisted; one subgroup fared better on targeted drugs. The authors conclude chemotherapy remains the backbone for most of these patients.
Catalog record
| CREATOR | Jianlin Xu, Anshun Zhu, Yingqi Xu, Yidan Zhang, Yinchen Shen, Yongliang Niu, Hua Zhong, Runbo Zhong |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |